COMMUNIQUÉS West-GlobeNewswire
-
MedShop Direct Expands White Glove Delivery and Installation of Adjustable Medical Beds for Assisted Living and Home Care Across 48 States
22/04/2026 -
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
22/04/2026 -
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
22/04/2026 -
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
22/04/2026 -
Amae Health and Novant Health bring enhanced integrated care model for severe mental illness to Charlotte, North Carolina
22/04/2026 -
Three-Peat: Becker’s Healthcare Dubs U.S. Oral Surgery Management a DSO to Know
22/04/2026 -
Eleos Expands AI Agents Across the Full Care Journey
22/04/2026 -
Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning
22/04/2026 -
EmblemHealth Expands Community Diabetes Wellness Program, Bringing Free, Citywide Support to New Yorkers
22/04/2026 -
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
22/04/2026 -
PerfectServe Ranks #1 Across All Use Cases in the Gartner® Critical Capabilities for Clinical Communication and Collaboration Report
22/04/2026 -
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
22/04/2026 -
OneMedNet Goes Live with 80 Million Patient Journeys and Billions of Records
22/04/2026 -
LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer
22/04/2026 -
NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody
22/04/2026 -
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
22/04/2026 -
Repligen to Report First Quarter 2026 Financial Results
22/04/2026 -
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
22/04/2026 -
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
Pages